Kiplinger

15 Large-Cap Stocks Betting Big on M&A

The right mergers and acquisitions (M&A) can make a good company even better by opening up new markets, expanding capabilities and market share, and diversifying product lines.

Not every deal is a guaranteed winner, but investors typically benefit from smart M&A. A 2016 Booth Business School study found, on average, an increase in overall value for both the acquiring and acquired companies at the time of the merger, and a long-term rise in value for companies that made cash acquisitions.

Consider the $81 billion merger between Exxon and Mobil in 1999 that created Exxon Mobil (XOM) - now a $300 billion goliath and the largest publicly traded energy company on U.S. exchanges. Or there's Walt Disney's (DIS) $6 billion buyout of Pixar in 2006. The studio's animated films have generated nearly $11 billion in worldwide box office alone, not accounting for merchandise and other related opportunities.

Last year was an especially good year for corporate M&A thanks to major catalysts provided by tax reform, low borrowing costs and a healthy stock market. Dealmaking hit near-record levels last year. According to Mergermarket, 5,718 transactions closed, and deal volume exceeded $1.5 trillion - the second-highest total ever. Also noteworthy was last year's surge in "mega-deals" - transactions valued at more than $10 billion. These included Keurig Dr. Pepper's (KDP) $27 billion acquisition of soft drink maker Dr. Pepper Snapple Group and pharmacy chain CVS Health's (CVS) $70 billion takeover of health insurance provider Aetna.

Here are 15 large-cap stocks that are looking for big things out of their pending or recently closed M&A deals. These mergers and acquisitions are either already sparking new life in the acquiring companies, or analysts and other market professionals expect them to do so over the coming years.

Cigna

Getty Images

Market value: $61.3 billion

Target company: Express Scripts

Deal value: $67.0 billion

Deal close: Dec. 20, 2018

Health insurance giant Cigna (CI, $162.34) expects to trim healthcare costs by managing both medical and prescription drug benefits for customers. To that end, the company acquired pharmacy benefits manager Express Scripts in 2018. Cigna embraced an integrated services model already pioneered by UnitedHealth Group (UNH), which acquired OptumRX, and CVS Health, which in addition to buying Aetna owns pharmacy benefits manager Caremark.

Cigna is focusing on a seamless integration this year. In 2020, it plans to begin rolling out new services that capitalize on its combined medical and pharmacy capabilities, including enhanced offerings in specialty pharmaceuticals and mental health.

The merger was a cash-and-stock deal in which Cigna also assumed $15 billion of Express Scripts debt. The deal represented a 31% premium to Express Scripts value, and activist Carl Icahn initially opposed the merger because of the high price. But he changed his position after Institutional Shareholder Services recommended the deal for being significantly accretive to earnings per share (EPS). Cigna is guiding for 2021 EPS of $20 to

You’re reading a preview, subscribe to read more.

More from Kiplinger

Kiplinger4 min read
This New Sustainable ETF’s Pitch? Give Back Profits.
Feel like society and the environment are beginning to break down? There’s an ETF for that. Newday Impact’s Sustainable Development Goals ETF (SDGS) delivers a growth-oriented product that promotes dual impact, promising to advocate for environmental
Kiplinger3 min read
Cryptocurrency: Stay In? Get Out? How to Decide?
Warren Buffett is famous for saying “Only when the tide goes out do you discover who's been swimming naked.” If you invested in cybercoins, the news has not been good lately. Are you wearing your bathing suit?  What to do?  Is time to take your profi
Kiplinger4 min read
Got Crypto? The IRS Really Wants to Know
The 2022 crypto price crash understandably has some investors concerned. But for those of you who haven’t run for the hills, it’s worth knowing that cryptocurrency currently has the attention of not only the Biden administration, and Congress, but th

Related